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Neurobiology of Disease

Anti-ApoE Antibody Given after Plaque Onset Decreases A␤
Accumulation and Improves Brain Function in a Mouse
Model of A␤ Amyloidosis
Fan Liao,1,2,3 Yukiko Hori,6 Eloise Hudry,6 Adam Q. Bauer,4 Hong Jiang,1,2,3 Thomas E. Mahan,1,2,3
Katheryn B. Lefton,1,2,3 Tony J. Zhang,1,2,3 Joshua T. Dearborn,5 Jungsu Kim,8 Joseph P. Culver,4 Rebecca Betensky,9
David F. Wozniak,2,5,7 Bradley T. Hyman,6 and David M. Holtzman1,2,3
1

Department of Neurology, 2Hope Center for Neurological Disorders, 3Charles F. and Joanne Knight Alzheimer’s Disease Research Center, 4Department of
Radiology, and 5Department of Psychiatry, Washington University School of Medicine, St. Louis, Missouri 63110, 6MassGeneral Institute for
Neurodegenerative Disease, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts 02129, 7The Taylor Family Institute
for Innovative Psychiatric Research, Washington University School of Medicine, St. Louis, Missouri 63110, 8Department of Neuroscience, Mayo Clinic
College of Medicine, Jacksonville, Florida 32224, and 9Harvard School of Public Health, Boston, Massachusetts 02115

Apolipoprotein E (apoE) is the strongest known genetic risk factor for late onset Alzheimer’s disease (AD). It influences amyloid-␤ (A␤)
clearance and aggregation, which likely contributes in large part to its role in AD pathogenesis. We recently found that HJ6.3, a monoclonal antibody against apoE, significantly reduced A␤ plaque load when given to APPswe/PS1⌬E9 (APP/PS1) mice starting before the
onset of plaque deposition. To determine whether the anti-apoE antibody HJ6.3 affects A␤ plaques, neuronal network function, and
behavior in APP/PS1 mice after plaque onset, we administered HJ6.3 (10 mg/kg/week) or PBS intraperitoneally to 7-month-old APP/PS1
mice for 21 weeks. HJ6.3 mildly improved spatial learning performance in the water maze, restored resting-state functional connectivity,
and modestly reduced brain A␤ plaque load. There was no effect of HJ6.3 on total plasma cholesterol or cerebral amyloid angiopathy. To
investigate the underlying mechanisms of anti-apoE immunotherapy, HJ6.3 was applied to the brain cortical surface and amyloid
deposition was followed over 2 weeks using in vivo imaging. Acute exposure to HJ6.3 affected the course of amyloid deposition in that it
prevented the formation of new amyloid deposits, limited their growth, and was associated with occasional clearance of plaques, a process
likely associated with direct binding to amyloid aggregates. Topical application of HJ6.3 for only 14 d also decreased the density of
amyloid plaques assessed postmortem. Collectively, these studies suggest that anti-apoE antibodies have therapeutic potential when
given before or after the onset of A␤ pathology.
Key words: Alzheimer’s; amyloid; antibody; apolipoprotein E

Introduction
Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by the impairment of memory and other cognitive
functions, as well as the presence of extracellular amyloid plaques
and intracellular neurofibrillary tangles (Holtzman et al., 2011).
There is substantial evidence indicating that amyloid-␤ (A␤)
plays a key role in the development of AD (Hardy and Selkoe,
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2002; Lemere and Masliah, 2010). Previous therapeutic strategies
for AD, including A␤ immunotherapy (Schenk et al., 1999; Bard
et al., 2000), have focused on decreasing A␤ accumulation or
removing existing A␤ aggregates by enhancing A␤ clearance.
Certain types of active and passive immunization have resulted in
significant side effects such as brain edema and hemorrhages
(Brody and Holtzman, 2008). Given that A␤ metabolism is regulated by A␤-binding proteins, immunization approaches targeted against proteins that regulate A␤ metabolism could also
provide another treatment avenue, potentially with fewer side
effects.
The 4 allele of apolipoprotein E (apoE) has been established
as the strongest genetic risk factor for late-onset AD (Corder et
al., 1993; Strittmatter et al., 1993a; Strittmatter et al., 1993b;
Corder et al., 1994; Belinson and Michaelson, 2009). There is
compelling evidence showing that apoE affects A␤ accumulation
by modulating both A␤ aggregation (Ma et al., 1994; Wisniewski
et al., 1994) and clearance (Sadowski et al., 2006; Deane et al.,
2008; Jiang et al., 2008; Castellano et al., 2011) and it also colocalizes with A␤ plaques (Namba et al., 1991). Recently, we found
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that passive immunization of APPswe/PS1⌬E9 (APP/PS1) mice
before A␤ plaque onset resulted in a strong decrease of A␤
plaques and insoluble A␤40 and A␤42 levels (Kim et al., 2012).
However, it is unknown whether passive apoE immunotherapy
that begins after the presence of amyloid deposition in the brain
would have similar effects. In addition, the potential mechanisms
of the anti-amyloid effects and whether apoE immunotherapy
benefits brain function have not been explored.
Here, we treated 7-month-old APP/PS1 mice that had preexisting A␤ plaques with the anti-apoE monoclonal antibody HJ6.3
for 21 weeks. We assessed changes in spatial learning and memory, intrinsic functional connectivity, and A␤ pathology associated with this treatment. In addition, we examined possible side
effects including hypercholesterolemia, cerebral amyloid angiopathy (CAA), and CAA-associated microhemorrhage. With the
aim of understanding the mechanisms of anti-apoE immunotherapy dynamically, we performed in vivo 2-photon imaging
over 2 weeks after acute HJ6.3 exposure to the cortical surface.
The results suggest that HJ6.3 prevents new plaque formation,
inhibits A␤ plaque growth, favors the clearance of amyloid aggregates, and improves brain function.

Materials and Methods
Chronic antibody administration and pathology assessment. Sevenmonth-old female APPswe/PS1⌬E9 (APP/PS1) mice on a B6C3 background (Jankowsky et al., 2004) were injected intraperitoneally with a
weekly dose of 10 mg/kg body weight of anti-apoE mouse monoclonal
antibody HJ6.3 (Kim et al., 2012) or PBS for 21 weeks. HJ6.3 is an IgG2b
antibody. During the last 4 weeks of treatment, behavioral performance
of the mice was tested. Two days after the final injection, functional
connectivity optical intrinsic signal imaging (fcOIS) was recorded. Immediately after fcOIS, blood was collected via cardiac puncture and then
the mice were perfused with ice-cold PBS containing 0.3% heparin. One
hemibrain was fixed in 4% paraformaldehyde for histological analysis of
amyloid plaque load, CAA, CAA-associated microhemorrhages, apoE,
and microglial immunoreactivity. The other hemibrain was dissected
and flash-frozen on dry ice for biochemical assays for A␤ and apoE. Data
in all the figures are expressed as mean ⫾ SEM unless otherwise specified.
All experimental protocols were approved by the Animal Studies Committee at Washington University, Massachusetts General Hospital Subcommittee for Research, and the Animal Care and Use Committee at
Harvard Medical School.
Immunohistochemistry. Serial coronal sections at 50 m thickness
were collected from the rostral to the caudal end of each brain hemisphere using a freezing sliding microtome (Leica). A␤ plaques were immunostained using biotinylated anti-A␤1–13 monoclonal antibody
HJ3.4B (Bero et al., 2012). ApoE was immunostained using anti-apoE
HJ6.8B (generated in-house), which recognizes a different epitope of
apoE than HJ6.3. Activated microglia were immunostained using ratanti CD45 (AbD Serotec), followed by biotinylated goat anti-rat IgG
secondary antibody (Life Technologies). Quantitative analysis of immunopositive staining was performed as described previously (Bero et al.,
2012). Briefly, images of immunostained sections were exported with
NDP viewer (Hamamatsu Photonics), converted to 8-bit grayscale using
ACDSee Pro 2 software (ACD Systems), thresholded to highlight positive
staining, and analyzed using ImageJ software. Three sections per mouse
(bregma, ⫺1.4 mm caudal to bregma, ⫺2.0 mm caudal to bregma) were
quantified (hippocampus and overlying cortex) and the average was used
to represent each mouse. For CAA quantification, the values from individual mice were normalized according to the average value of control
group. Two-tailed Student’s t test was used to analyze the data.
ELISA. Brain cortices were sequentially homogenized with cold PBS,
1% Triton-X 100, and 5 M guanidine buffer in the presence of 1⫻ protease inhibitor mixture (Roche). The levels of A␤x-40 and apoE were
measured by sandwich ELISA. For A␤x-40 ELISA, anti-A␤35– 40 HJ2 was
used as a capture antibody and anti-A␤13–18 HJ5.1-biotin (Bero et al.,
2011) was used as the detecting antibody. For apoE, HJ6.4 (Kim et al.,
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2012) was used as the capture antibody and HJ6.1-biotin (Kim et al.,
2012) as the detecting antibody. Pooled C57BL/6J plasma was used as a
quantification standard for murine apoE (Kim et al., 2012). Two-tailed
Student’s t test was used to analyze the data.
Total plasma cholesterol. Total plasma cholesterol was assessed using a
commercial kit (catalog #439-17501; Wako Chemicals) following the
manufacturer’s instructions. Two-tailed Student’s t test was used to analyze the data.
Staining and quantitative analysis of CAA-associated microhemorrhage.
Prussian blue staining was performed to identify microhemorrhages
(Fryer et al., 2003). Briefly, 15–18 equally spaced 50 m sections, 300 m
apart, were assessed from each mouse. Sections were mounted on Superfrost slides and dried overnight. Sections were rehydrated in PBS, followed by permeablizing in PBS–Triton X-100 (0.25%) for 10 min. After
being washed twice with 0.9% NaCl for 2 min/each, sections were incubated in 2% HCl containing 2% potassium ferrocyanide for 20 min. After
washing with PBS, the sections were costained with 0.025% Thioflavin S
(ThioS) to confirm that any putative microhemorhages were associated
with CAA. The blue puncta stained by Prussian blue were counted with a
light microscope. ThioS staining was visualized under the 488 nm fluorescent emission range. Two-tailed Student’s t test was used to analyze
the data.
One hour locomotor activity and sensorimotor battery. Locomotor activity was evaluated in HJ6.3-treated (n ⫽ 19) and PBS-treated (n ⫽ 18)
mice over a 1 h period using transparent (47.6 ⫻ 25.4 ⫻ 20.6 cm high)
polystyrene enclosures and computerized photobeam instrumentation, as described previously (Wozniak et al., 2004). Variables pertaining to general ambulatory activity (total ambulations) and
exploratory behaviors (vertical rearings) were analyzed. All mice were
also evaluated on a battery of sensorimotor tests to assess balance
(ledge and platform), strength (inverted screen), coordination (pole
and inclined screens), and initiation of movement (walking initiation) using previously published procedures (Wang et al., 2002;
Wozniak et al., 2004). One-way ANOVA models were used to analyze
differences between groups.
Morris water maze navigation. Spatial learning and memory capabilities of the APP/PS1 mice were assessed in the Morris water maze (MWM)
after 4 –5 months of treatment with HJ6.3 or PBS at 11–12 months of age
using a computerized tracking system (ANY-maze; Stoelting) that involved procedures similar to those previously described (Wozniak et al.,
2004). The protocol included conducting cued (visible platform), place
(submerged and hidden platform), and probe (platform removed) trials
in a round pool (118 cm inner diameter) of opaque water. Mice were first
trained on the cued condition (11 months of age) to determine whether
nonassociative factors were likely to affect acquisition performance during subsequent place trials. Unlike our typical water maze procedures, in
which mice experience 2 consecutive days of cued trials, the mice in the
present study received 4 trials per day (60 s maximum) for 5 consecutive
days in an effort to provide additional training to compensate for potentially poor swimming abilities in the APP/PS1 mice. The cued trials involved moving the platform to a different location for each trial using a
30 min intertrial interval (ITI) in the presence of very few distal spatial
cues to limit spatial learning. Three days after completing the cued trials,
the mice were trained on the “place” condition to learn the location of a
submerged platform. The place trials were conducted in the presence of
several salient distal cues positioned around the room to facilitate association of the spatial cues with the submerged platform, which remained
in the same location for all trials. During the place trials, the mice received 2 blocks of 2 consecutive trials (60 s maximum for a trial; 30 s ITI
spent on platform), with each block being separated by ⬃2 h and each
mouse being released from a different quadrant for each trial. The place
trials data were analyzed over 5 blocks of trials (4 trials/block) in which
each block represented the performance level for each of 5 consecutive
days. Escape path length, latency, and swimming speeds were analyzed as
performance variables for the cued and place trials. A probe trial was
administered ⬃1 h after completion of the place trials on the fifth day of
testing to evaluate retention of the platform location. During the 60 s
probe trial, the escape platform was removed and a mouse was placed in
the quadrant diagonally opposite from the previous platform location.
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Times spent in the pool quadrants and the number of crossings made
over the platform location (platform crossings) were recorded. Repeatedmeasures ANOVA (rmANOVA) models containing one between-subjects
variable (treatment) and one within-subjects (repeated measures) variable
(e.g., blocks of trials) were typically used to analyze the learning and memory
data. The Huynh–Feldt adjustment of ␣ levels was used for all withinsubjects effects containing more than two levels to protect against violations of sphericity/compound symmetry assumptions underlying
rmANOVA models. Pairwise comparisons were conducted after relevant, significant overall rmANOVA effects, which were subjected to Bonferroni’s correction when appropriate.
fcOIS. Following a previously published fcOIS protocol (White et al.,
2011), mice were anesthetized with ketamine-xylazine (108 mg/kg ketamine, 17 mg/kg xylazine) and were placed on a rectally monitored heating pad maintained at 37°C (mTCII; Cell Microcontrols) with the head
secured in a stereotactic frame. A midline incision was made, the scalp
reflected, and the intact skull was kept moist with mineral oil. Sequential
illumination was provided at four wavelengths by a ring of light-emitting
diodes (LEDs) placed ⬃10 cm above the head (for details, see White et al.,
2011). Diffuse reflected light was detected by a cooled, frame-transfer
EMCCD camera (iXon 897; Andor Technologies). The LED ring and
camera were computer controlled and operated at a full frame rate of 30
Hz. The field of view covered the majority of the convexity of the cerebral
cortex (⬃1 cm 2). Data from all mice were subjected to an initial quality
check before spectroscopic analysis. Data runs (5 min) in which temporal
variation in reflected light level intensity exceeded 1% for any wavelength
were excluded from further analysis. This preliminary analysis resulted in
15– 45 min of data per mouse. For each pixel, the differential light intensity at each wavelength was converted to differential absorption. The
multiwavelength absorption coefficient data were then converted to hemoglobin concentration changes for each pixel and time point. The subsequent fc analysis used the spatiotemporal ⌬HbO2 data (White et al.,
2009). Data were filtered to the functional connectivity band (0.009 –
0.08 Hz) following previous human fMRI algorithms (Fox et al., 2005),
resampled from 30 to 1 Hz, and a brain mask was created containing all
pixels labeled as brain. Time traces of all brain pixels were averaged to
create a global brain signal. This global signal was regressed from each
pixel’s time trace to remove global sources of variance, as is common in
human fMRI algorithms. All image sequences and brain masks were
affine transformed to a common atlas space (Franklin and Paxinos, 1996)
determined by the coordinates of olfactory bulb and cerebrum, bregma,
and lambda. The anterior–posterior stretch was set equal to the medial–
lateral stretch. To ensure that all comparisons were performed only on
the brain area visualized in all mice, the intersection of each brain mask
was calculated and made symmetric. Seed placement was determined a
priori using an anatomical atlas (Franklin and Paxinos, 1996). Four seed
locations were positioned at coordinates corresponding to left and right
motor, somatosensory, retrosplenial, and visual cortices. Seed time traces
were calculated by averaging time traces within 0.25 mm (30 pixels) of a
seed locus and functional connectivity maps were created by correlating
each seed time trace against those in every brain pixel. Individual functional connectivity maps were averaged within each cohort to generate
consensus maps for each cohort. Regional bilateral correlations were
determined by correlating the seed-based time trace in each functional
area with that of its contralateral homolog, thus producing six bilateral
correlation values for each mouse. Pearson r values were converted to
Fisher Z measures using: Z(r) ⫽ arctanh (r) for all group comparisons.
To further examine bilateral connectivity across the brain, every pixel in
the brain was used as a seed center and its time trace was correlated with
its contralateral homolog. Individual bilateral maps were averaged
within each cohort to generate consensus bilateral connectivity maps. To
calculate the number (degree) of functional connections of a given pixel
(node), the full pixel-to-pixel correlation matrix was computed for each
mouse over the entire brain. Any node having a correlation coefficient,
z(r), that was ⱖ0.25 was considered a connection and given a value of
1; those with a correlation coefficient ⬍0.25 were given a value of 0.
Summing over the rows of this binarized matrix produces an unweighted measure of node degree for all candidate regions. Statistical
significance was determined by one-tailed t test if two groups were
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Figure 1. Reduction of A␤ plaque deposition by the anti-apoE antibody HJ6.3. Sevenmonth-old female APP/PS1 mice received 10 mg/kg weekly intraperitoneal injections of HJ6.3
or PBS for 21 weeks. A, Brain sections of the HJ6.3- or PBS-treated mice were stained with the
anti-A␤ antibody HJ3.4B. Scale bar, 1 mm. B, A␤ plaque load in cortex, thalamus, and hippocampus were quantified (n ⫽ 13–17/group; *p ⬍ 0.05).

compared. When variance differed significantly between groups,
Welch’s t test was used. One-way ANOVA followed by Tukey’s post
hoc test for multiple comparisons were used when more than two
groups were compared.
Cranial window implantation, topical application of antibodies, and
multiphoton imaging. APP/PS1 mice were anesthetized with isoflurane
(1.5%) and a 4 mm piece of skull was drilled to expose the cortical surface
as described previously (Spires et al., 2005). After removing the dura, 50
l of each antibody stock (1.0 mg/ml) was topically applied before cementing the cranial window with a 5 mm glass coverslip. For a subset of
experiments, both anti-HA and anti-apoE HJ6.3 antibodies were labeled
with DyLight594 fluorophore following the manufacturer’s instructions
(Thermo Scientific). A wax ring was built along the border of the window
to create a wall of water for the objective during imaging. Each mouse
received an intraperitoneal injection of methoxy-XO4 (5 mg/kg) 24 h
before surgery, a fluorescent compound that crosses the blood– brain
barrier (BBB) and binds to plaques (Bacskai et al., 2002). Texas red or
fluorescein dextran (70,000 Da molecular weight; 12.5 mg/ml in sterile
PBS; Invitrogen) was also injected into a lateral tail vein to provide a
fluorescent angiogram so that the shape of the vasculature would be used
as a landmark to follow the exact same fields of view over time. Mice were
imaged right after surgery and 14 d thereafter. The density of plaque in
each field of view was quantified using ImageJ by reporting the total
number of amyloid deposits per volume of cortex imaged. Each cortical
volume was defined starting from surface of the brain to the last slice in
which an amyloid deposit could be detected. In vivo imaging data summarizing the amount of “stable,” “absent,” and “new” plaques were organized in a contingency table and analyzed using a  2 test. The size of
amyloid deposits was evaluated by measuring their cross-sectional area
from the maximal intensity after 2D projection. We calculated the ratio
between the size of each plaque just after surgery (t ⫽ 0) and 2 weeks
(t ⫽ 14 d) after topical application of each antibody. After the in vivo
imaging on t ⫽ 14 d, the mice were killed for postmortem analysis of
pathology. Data in all figures are expressed as mean ⫾ SEM unless
otherwise specified.
Multiphoton imaging. In vivo multiphoton imaging was performed
using an Olympus FluoView FV1000MPE multiphoton laser-scanning
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system mounted on an Olympus BX61WI
microscope and an Olympus 25⫻ objective
(numerical aperture ⫽ 1.05). A DeepSee Mai
Tai Ti:sapphire mode-locked laser (Mai Tai;
Spectra-Physics) generated two-photon excitation at 800 nm, and detectors containing
three photomultiplier tubes (Hamamatsu)
collected emitted light in the range of 420 –
460, 495–540, and 575– 630 nm. Mice were
placed on the microscope stage, heated using
a heating pad, and feedback regulation was
obtained from a rectal temperature probe
(Harvard Apparatus). Z-series (2 m steps,
depth of ⬃200 m, 512 ⫻ 512 pixels) were
taken to cover a large surface of the window.
The laser power was measured and adjusted
before each imaging and the settings of the
photomultiplier tubes were maintained unchanged throughout the different imaging
sessions.
Postmortem analysis after in vivo imaging.
Serial paraffin sections at 4 m thickness or
frozen sections at 40 m thickness were immunostained with rabbit anti-human amyloid␤
(N) antibody (Immuno-Biological Laboratories) and ThioS. Immunostained brain sections
were scanned using a Nanozoomer slide scanner (Hamamatsu Photonics). For the postmortem analysis after in vivo imaging, images were Figure 2. Attenuation of fibrillar amyloid deposition by the anti-apoE antibody HJ6.3. Seven-month-old female APP/PS1 mice
taken (1.25⫻, 20⫻) using an Olympus BX51 received 10 mg/kg weekly intraperitoneal injections of HJ6.3 or PBS for 21 weeks until 12 months of age. A, Fibrillar amyloid
epifluorescence upright microscope equipped plaques on brain sections of the HJ6.3- or PBS-treated mice were stained with ThioS. Scale bar, 500 m. B, Quantification of
with a CCD camera model DP70 (Olympus). fibrillar amyloid plaque load in cortex, thalamus, and hippocampus (n ⫽ 13–17/group; *p ⬍ 0.05; **p ⬍ 0.01).
For the localization analysis of HJ6.3 (see Fig.
10), images were acquired on a Zeiss LSM 510
META confocal microscope equipped with two-photon Coherent Chameleon laser. Quantitative analyses of amyloid load and plaque density
were done using the BIOQUANT software (version 6.90.10; MBSR) after
application of an optical threshold. This software is coordinated with the
motorized stage of an upright Leica DMRB microscope equipped with a
CCD camera (model DC330; DAGE-MTI). Immunostained amyloid
plaques were thresholded under the 10⫻ objective after background correction to avoid uneven lighting. Results of plaque load were analyzed
using a nonparametric Mann–Whitney test because the data did not
follow a normal distribution (according to the D’Agostino and Pearson
test). For each staining method independently, a mixed-effect model
with treatment as the fixed effect and mouse and section within mouse as
the random effects was fitted to assess the differences between treated
groups in the value of plaque size (with log of plaque size as the outcome)
while accounting for variability between mice and section within mice.
The plaque size ratios were compared between each treatment using
one-way ANOVA followed by post hoc Tukey multiple comparison tests.

Results

HJ6.3 decreased A␤ plaque load in the brain of APP/PS1 mice
To determine whether an anti-apoE antibody decreased A␤ deposition in APP/PS1 mice that had already developed significant
A␤ deposition, we assessed APP/PS1 mice after 5 months of peripheral administration of HJ6.3 (10 mg/kg/week). We immunostained A␤ plaques using an A␤-specific antibody HJ3.4B (Fig.
1A). In cerebral cortex immediately dorsal to the hippocampus,
HJ6.3 decreased plaque load by ⬃20% (Fig. 1B). In thalamus,
HJ6.3 decreased plaque load by a greater amount (⬃40%; Fig.
1B). In hippocampus, HJ6.3 did not significantly change plaque
load compared with the PBS group (Fig. 1B).
To determine whether fibrillar plaques were altered by HJ6.3,
we stained brain sections with ThioS (Fig. 2A). HJ6.3 significantly
reduced ThioS plaque load in cortex (Fig. 2B, top). In thalamus

Figure 3. Effects of the anti-apoE antibody HJ6.3 on brain apoE. Seven-month-old female
APP/PS1 mice received 10 mg/kg weekly intraperitoneal injections of HJ6.3 or PBS for 21 weeks.
ApoE in the cortex of the HJ6.3- or PBS-treated mice was immunostained with HJ6.8B (A) and
the percentage area covered by the staining was quantified (B) (n ⫽ 15–18/group; *p ⬍ 0.05;
**p ⬍ 0.01). Scale bar, 400 m.

(Fig. 2B, middle), plaque load was reduced by ⬃ 40%, whereas in
hippocampus, plaque load was not changed (Fig. 2B, bottom).
Changes of brain and blood apoE levels resulting from
HJ6.3 treatment
Because apoE is the direct target of the anti-apoE antibody HJ6.3,
we investigated whether peripheral administration of HJ6.3 al-
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Figure 4. Effects of the anti-apoE antibody HJ6.3 on A␤ and apoE levels in the brain and blood. A, The cortices of the HJ6.3- or PBS-treated mice were homogenized in PBS, followed
by 1% Triton X-100 and 5 M guanidine (Guan). ApoE and A␤x-40 levels in the brain tissue lysates in the PBS, Triton X-100, and Guan fractions were measured by ELISA. The level of apoE
and A␤x-40 in all fractions combined is also shown (n ⫽ 10 –18/group). B, Plasma apoE and A␤x-40 levels in HJ6.3- and PBS-treated animals were measured by ELISA (n ⫽ 15–18/group;
*p ⬍ 0.05; **p ⬍ 0.01).

tered apoE levels in brain and blood. Immunostaining using an
apoE antibody directed to a different apoE epitope, HJ6.8B,
showed decreased apoE immunostaining in the cerebral cortex in
HJ6.3-treated mice (Fig. 3 A, B). Biochemical analysis of apoE in
the brain tissue lysates demonstrated that apoE was decreased
primarily in the 1% Triton X-100 fraction, whereas the levels in
the PBS and 5 M guanidine fraction were unaltered (Fig. 4A, top).
In plasma, there was no change in apoE levels due to HJ6.3 (Fig.
4B, top).
HJ6.3 influenced A␤ levels in brain and blood
To determine whether the anti-apoE antibody HJ6.3 affects A␤
accumulation and solubility in the brain, we did a three-step
sequential extraction of cortical tissue using PBS, 1% Triton
X-100, and 5 M guanidine. A␤x-40 was then analyzed in each fraction (Fig. 4A). In the PBS-soluble fraction, HJ6.3 treatment had
no significant effects on A␤x-40. In the Triton X-100 fraction, in
which the apoE level was significantly lower in the HJ6.3-treated
group, A␤x-40 was significantly reduced by HJ6.3. In the 5 M guanidine fraction, which contains the insoluble A␤ and ⬎100⫻ the
A␤ present in the other fractions, A␤x-40 was reduced significantly. The combination of all fractions of A␤x-40 showed similar
findings as the guanidine fraction because this fraction contains
the majority of A␤ in the brain of plaque-bearing mice (Fig. 4A).
In plasma, HJ6.3 treatment resulted in a 40 – 60% increase in
A␤x-40 without affecting apoE levels (Fig. 4B).
Effects of HJ6.3 on microglial activation
To determine whether HJ6.3 had an impact on microglial activation, we immunostained brain sections of the mice treated with
HJ6.3 or PBS using CD45, a marker of activated microglia (Fig.
5A). In cerebral cortex, the CD45 staining load was decreased by
40% after HJ6.3 treatment (Fig. 5B).
Anti-apoE antibody HJ6.3 improves spatial learning but slows
motor responses
To determine whether HJ6.3 produced functional effects in APP/
PS1 mice, we assessed HJ6.3- or PBS-treated mice starting at 11

Figure 5. Effects of the anti-apoE antibody HJ6.3 on microglial activation. Seven-month-old
female APP/PS1 mice received 10 mg/kg weekly intraperitoneal injections of HJ6.3 or PBS for 21
weeks until 12 months of age. Activated microglia in the cortex were immunostained with
anti-CD45 antibody (A) and the area covered by CD45 staining was quantified (B) (n ⫽ 15–18/
group; *p ⬍ 0.05). Scale bar, 400 m.

months of age on several behavioral tests 4 months after beginning treatment. We first evaluated the mice on a 1 h locomotor
activity test and a battery of sensorimotor measures followed by
the MWM. The rmANOVAs conducted on the cued trials data
from the MWM showed that the HJ6.3- and PBS-treated groups
did not differ in terms of path length (Fig. 6A) or latency (data not
shown) to find the platform and escape out of the water. This
suggests that the two groups exhibited similar levels of cued
learning performance. However, the results of an rmANOVA
revealed that the HJ6.3-treated mice swam significantly more
slowly than the PBS-treated group during certain blocks within
the cued trials (treatment effect: F(1,35) ⫽ 6.99, p ⫽ 0.012; treatment ⫻ blocks of trials interaction: F(4,140) ⫽ 3.37, p ⫽ 0.025).
Subsequent pairwise comparisons showed that significant differ-
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ences were found for block 3 ( p ⫽ 0.004)
and large differences were also observed
on blocks 2 ( p ⫽ 0.037), 4 ( p ⫽ 0.014),
and 5 ( p ⫽ 0.015). Together, these results
suggest that nonassociative influences
(e.g., sensorimotor, visual, or motivational disturbances) did not affect the performance of the HJ6.3-treated mice
relative to the PBS-treated controls in
terms of simple cued learning. Due to differences in swimming speeds, we used
path length to evaluate acquisition performance in the place trials of the water
maze.
In contrast to the cued trials results, an
rmANOVA of the path length data from
the place (spatial learning) trials showed
that the HJ6.3-treated mice had significantly shorter path lengths to the submerged platform across trials (Fig. 6B)
compared with the PBS-treated control
mice (treatment effect: F(1,35) ⫽ 4.79, p ⫽
0.035), with differences being greatest
during block 3 ( p ⫽ 0.019). In addition,
similar to the results from the cued trials,
the HJ6.3-treated mice swam significantly
more slowly than the PBS-treated controls
during certain blocks within the place trials (treatment effect: F(1,35) ⫽ 13.51, p ⫽
0.0008; treatment ⫻ blocks of trials inter- Figure 6. HJ6.3 treatment improved spatial learning performance in the MWM. Seven month-old female APP/PS1 mice received 10 mg/kg weekly intraperitoneal injections of HJ6.3 or PBS for 21 weeks until 12 months of age. During the last 4 weeks of
action: F(4,140) ⫽ 4.01, p ⫽ 0.005), with
treatment, the performance of HJ6.3-treated (n ⫽ 19) and PBS-treated (n ⫽ 18) mice in the MWM task was tested. A, The HJ6.3pairwise comparisons showing that sig- and PBS-treated mice did not differ in performance with regard to path length during the cued trials. B, However, the HJ6.3-treated
nificant differences occurred during mice exhibited significantly improved performance in terms of showing decreased path length during the place (spatial learning)
blocks 2–5 ( p ⬍ 0.001). Analysis of the trials compared with the PBS-treated group (treatment effect: *p ⫽ 0.035), with differences being greatest during block 3 (†p ⫽
probe trial data indicated that the groups 0.019). C, PBS-treated mice did not show a spatial bias for the target quadrant during the probe trial because they did not spend
did not differ in terms of platform cross- significantly more time in that quadrant compared with the times in each of the other quadrants. In contrast, the HJ6.3-treated
ings (data not shown) or time spent in the mice did show a spatial bias for the target quadrant because they spent significantly more time in the target quadrant compared
target quadrant. The HJ6.3-treated mice with the times spent in each of the other pool quadrants (*p ⬍ 0.014).
did, however, show a spatial bias for the
cohort (Fig. 7C). Compared with PBS-treated mice, bilateral
target quadrant (Fig. 6C) in that they spent significantly more
functional connectivity in the HJ6.3 group appeared to be more
time in the target quadrant relative to the times they spent in each
globally restored and to resemble that of healthy, wild-type mice
of the other quadrants ( p ⬍ 0.014), whereas the PBS-treated
(Fig. 7C), as described previously (White et al., 2011; Bero et al.,
group did not show a spatial bias for the target quadrant. Overall,
2012). Although bilateral connectivity magnitude provides a usethese results suggest that HJ6.3 improved spatial learning in APP/
PS1 mice.
ful metric of homotopic interhemispheric connectivity, this is
only a limited measure of the rich connectivity structure otherHJ6.3 improves brain functional connectivity in
wise observed over the mouse brain. To examine more closely the
APP/PS1 mice
effects of HJ6.3 on the topology of functional connectivity, we
To determine whether HJ6.3 antibody treatment restored disanalyzed the number of functional connections (node degree) in
rupted functional connectivity in the mouse brain, we compared
the four brain regions investigated (Fig. 7D). From this analysis,
functional connectivity patterns (Fig. 7A) in APP/PS1 mice
we observed significant increases in the node degree of motor,
treated with HJ6.3 and PBS using fcOIS (White et al., 2011; Bero
somatosensory, retrosplenial, and visual cortices compared with
et al., 2012). We have shown previously that fcOIS is a sensitive
the PBS-treated group.
imaging modality capable of measuring functional connectivity
between brain regions in healthy mice (White et al., 2011; Bero et
Lack of potential side effects on cholesterol, CAA, and
al., 2012) and that there is functional disruption in APP/PS1 mice
CAA-associated microhemorrhage
after A␤ deposition (White et al., 2011; Bero et al., 2012). APP/
Being a key apolipoprotein in certain lipoprotein complexes,
PS1 mice treated with HJ6.3 exhibited improved bilateral funcapoE plays an important role in plasma lipid metabolism. Given
tional correlation strength in visual cortex with trends toward
that the plasma cholesterol level of apoE-deficient mice is fivefold
improvement in motor and somatosensory cortices (Fig. 7 A, B).
higher than that of wild-type mice, a potential side effect of apoE
To more closely assess the effects of HJ6.3 on global bilateral
passive immunotherapy is that the apoE antibodies could elevate
functional connectivity, full-field bilateral functional connectivthe cholesterol level by lowering plasma apoE levels or blocking
ity maps were created for every mouse and averaged within each
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in CAA-associated microhemorrhage
associated with HJ6.3 administration
(Fig. 8C).
Topical application of the anti-apoE
HJ6.3 dynamically alters amyloid
deposition over 2 weeks
To further assess early dynamic changes in
amyloid deposition associated with apoE
immunotherapy, HJ6.3 or IgG subtypematched anti-HA (i.e., irrelevant epitope)
control antibodies were topically applied
to the surface of brain and in vivo twophoton microscopy was used to monitor
A␤ plaques the day of surgery (t ⫽ 0) and
14 d after antibody treatment (t ⫽ 14 d).
After 2 weeks of incubation, the same
fields of view were imaged again and amyloid plaques were classified as “absent”
when they could not be found again, “stable” when they were imaged again, and
“new” for newly formed deposits over the
Figure 7. HJ6.3 treatment improved brain functional connectivity assessed by fcOIS. Seven-month-old female APP/PS1 mice 2 weeks of incubation. Although most dereceived 10 mg/kg weekly intraperitoneal injections of HJ6.3 or PBS for 21 weeks. At the age of 12 months, fcOIS was performed to posits were stable over time, direct appliassess the resting state functional connectivity of the brain before euthanizing the mice. A, Composite, group-averaged, functional cation of HJ6.3 reduced the amount of
correlation maps of motor, somatosensory, retrosplenial, and visual cortices in HJ6.3-treated (n ⫽ 15) and PBS-treated (n ⫽ 14) newly formed plaques (“new” plaques)
APP/PS1 mice. Black circles denote seed position. B, Regional bilateral functional correlation of PBS-treated (blue) and HJ6.3- and was associated with clearance of some
treated (red) APP/PS1 mice. C, Consensus bilateral functional connectivity maps generated for HJ6.3 and PBS treated APP/PS1 mice amyloid deposits (“absent” plaques; Fig.
and age-matched untreated wild-type B6C3 mice. The maps for age-matched wild-type B6C3 mice were regenerated from the 9 A, B).
data reported in Bero et al. (2012). D, Node degree in motor, somatosensory, retrosplenial, and visual cortices (*p ⬍ 0.05; **p ⬍
To further establish the connection be0.01).
tween the presence of anti-apoE antibody
and changes in amyloid deposition,
fluorescent-labeled DyLight 594-HJ6.3
antibody was applied to the surface of the
brain. We confirmed that the anti-apoE
antibody HJ6.3 can bind directly to intraparenchymal amyloid deposits and to
CAA (Fig. 10A). Some A␤ plaques, especially those located deeper within the cortical parenchyma, were not stained with
DyLight 594-HJ6.3 antibody, likely due to
limitations in diffusion over the several
hours of observation. To determine the
Figure 8. No effects of HJ6.3 on plasma cholesterol, CAA, or CAA-associated microhemorrhage. Seven-month-old APP/PS1 mice
type of plaques that were bound by DyLight
received 10 mg/kg weekly intraperitoneal injections of HJ6.3 or PBS for 21 weeks until 12 months of age. A, Total plasma
594-HJ6.3, brain sections were immunocholesterol levels. B, CAA on the surface of the cortex was identified by anti-A␤ antibody HJ3.4B immunostaining and the area
covered by CAA was quantified. C, CAA-associated microhemorrhage was detected by Prussian blue and ThioS costaining (n ⫽ stained with anti-A␤ antibody after the application of the DyLight 594-conjugated
13–18/group).
antibody. Immunohistochemistry showed
that DyLight 594-HJ6.3 can also bind
small, methoxy-XO4-negative nonfibrilapoE function. We found that injection of the anti-apoE antilar
plaques,
as
well
as
methoxy-XO4-positive fibrillar plaques
body HJ6.3 did not affect plasma cholesterol (Fig. 8A).
10B).
Interestingly,
we observed that 91% of the “absent”
(Fig.
In previous studies of active and passive immunization inplaques
that
could
not
be
detected after 14 d were previously
volving the generation of certain anti-A␤ antibodies, an increase
labeled with HJ6.3 (Fig. 11 A, B). At the same time, 56% of “staof CAA and CAA-associated microhemorrhage has been obble” plaques were also bound by HJ6.3, but the ratio of plaque size
served (Pfeifer et al., 2002). To determine whether passive immuof these deposits decreased between 0 and 14 d, a change that was
notherapy targeting apoE results in similar side effects, we
not observed with nonlabeled plaques or with the anti-HA conassessed CAA and CAA-associated microhemorrhage. The CAA
trol antibody (Fig. 11C,D). We therefore concluded that topical
present on the cortical surface stained with A␤-specific antibody
application of anti-apoE antibody HJ6.3 acutely modified the
HJ3.4B was quantified. HJ6.3 did not alter the relative area covcourse of amyloid deposition over 2 weeks, leading to the clearered by CAA compared with the PBS-treated group (Fig. 8B). The
ance of a small percentage of amyloid plaques while leading to
amount of CAA-associated microhemorrhage in APP/PS1 mice
at 12 months of age was low and we did not detect any increase
shrinkage of others, a process associated with a direct interaction
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Figure 9. In vivo imaging of A␤ plaques after topical application of the anti-apoE antibody HJ6.3. Fifty microliters of the anti-apoE antibody HJ6.3 or anti-HA control antibody (1.0 mg/ml) were
topically applied to the brain surface of 5- to 7-month-old APP/PS1 mice. Plaques were monitored through the cranial window using two-photon microscopy the day of surgery and 14 d after
treatment, following the exact same fields of view over time. A, Representative in vivo images of amyloid plaques the day of surgery (t ⫽ 0) and 14 d (t ⫽ 14 d) after topical application of control
(anti-HA) or the anti-apoE antibody HJ6.3. Yellow and white arrows respectively show “absent” and “new” plaques. Scale bar, 100 m. B, Contingency table summarizing the number of “absent,”
“stable,” and “new” plaques 2 weeks after topical application of the anti-apoE antibody HJ6.3 and anti-HA antibodies (n ⫽ 7/group; p ⬍ 0.0001,  2 test).

between the anti-apoE antibody and apoE
present within A␤ deposits.
Acute exposure with HJ6.3 also affects
nonfibrillar A␤ plaques
As mentioned previously, acute exposure
with HJ6.3 for 2 weeks significantly altered the dynamic of amyloidosis, a phenomenon associated with the direct
binding of anti-apoE antibody to apoEbound amyloid deposits. We then aimed
at determining whether these changes
could also be observed by postmortem
immunohistological analysis. Amyloid
load and amyloid plaque density were
evaluated 15 d after topical application
with the anti-apoE HJ6.3 or anti-HA antibodies (Fig. 12A). The stereological
analysis specifically focused on the amyloid deposits present within the cortical
area underneath the cranial window. To
correct for interindividual variability, the
results were normalized for each mouse
for the amount of plaques in the hippocampus, a deeper cerebral area that was
not in contact with the antibodies. The
plaque number per square millimeter after HJ6.3 topical application was significantly lower by 40% compared with
anti-HA control antibody (Fig. 12C);
however, the plaque load per square millimeter was not changed significantly (Fig.
12B). This was likely because the overall
effect on plaques was modest and the
plaques most affected have the smallest
cross-sectional area and thus likely have a
proportionately small impact on the measure of amyloid burden. Surprisingly,
ThioS staining showed no differences in

Figure 10. Affinity of fluorescent-labeled DyLight 594-apoE antibody HJ6.3 to CAA and A␤ plaques. Fifty micrograms of
fluorescently labeled DyLight 594-apoE antibody HJ6.3 or DyLight 594-anti-HA control antibody (1.0 mg/ml) were topically
applied to the brain surface of 5- to 7-month-old APP/PS1 mice. Plaques and CAA were imaged by in vivo two-photon microscopy
and immunohistochemistry with the rabbit anti-human A␤ (N) antibody (Immuno-Biological Laboratories). A, Representative
photographs of in vivo imaging after 30 min of incubation with antibody, showing that only the DyLight 594-apoE antibody HJ6.3
can bind apoE in CAA (yellow arrow) and amyloid plaques (white arrow) after a single topical application to the brain. Scale bar, 100
m. B, Representative photographs of immunohistochemistry after 2 h of incubation with antibody, showing that the DyLight
594-apoE antibody HJ6.3 can bind apoE in small, methoxy-XO4-negative amyloid plaque (yellow arrow) and in a methoxy-XO4positive amyloid plaque (white arrow) after a single topical application to the brain. Scale bar, 50 m.
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Figure 11. In vivo dynamic measurement of A␤ plaques after treatment with HJ6.3. Fifty microliters of fluorescently labeled DyLight 594-apoE antibody HJ6.3 or DyLight 594-anti-HA control
antibody (1.0 mg/ml) were topically applied to the brain surface of 5- to 7-month-old APP/PS1 mice. Plaques were monitored by two-photon microscopy. A, Representative in vivo images of the
fluorescently labeled DyLight 594-HJ6.3 and methoxy-XO4 the day of application (t ⫽ 0) or 14 d after (t ⫽ 14 d), showing that the plaque that got cleared (yellow arrow) was previously labeled by
DyLight 594-HJ6.3, as opposed to nonlabeled plaque (white arrow). Scale bar, 100 m. B, Contingency table summarizing the number of “absent,” “stable,” and “new” plaques according to their
initial binding with anti-apoE HJ6.3 and anti-HA antibodies. C, Representative in vivo images of the fluorescently labeled DyLight 594-HJ6.3 and methoxy-XO4 the day of application (t ⫽ 0) or 14 d
after (t ⫽ 14 d), showing that the size of HJ6.3-labeled plaque decreased after topical application of labeled HJ6.3 (yellow arrow), as opposed to nonlabeled plaque (indicated by white arrow). Scale
bar, 100 m. D, Graph bar indicating the size ratio between day 0 and day 14 after topical application of the control antibody or the anti-apoE antibody HJ6.3 (n ⫽ 3/group; *p ⬍ 0.05, ***p ⬍ 0.001
for one-way ANOVA followed by post hoc Tukey test and p ⬍ 0.0001 for  2 test).

either plaque load or plaque number per square millimeter (data
not shown) between HJ6.3 and anti-HA control antibody. In
addition, whereas the distribution of plaque size tended to show
that HJ6.3 topical application preferentially affected smaller deposits when assessed by immunohistological staining ( p ⬍ 0.075;
Fig. 12D), no such trend was observed with the ThioS staining
(data not shown). These results may indicate that, whereas small
changes were observed on dense-core plaques by in vivo twophoton imaging, acute exposure with anti-apoE antibody primarily decreased the density of less fibrillar small amyloid
deposits.

Discussion
In the present study, we report that peripheral weekly administration of apoE antibodies into mice with preexisting A␤ plaques
attenuates plaque load and insoluble A␤ without causing significant side effects such as hypercholesterolemia, CAA, or CAAassociated microhemorrhage. ApoE levels in the brain were
decreased by antibody treatment and A␤ levels in the blood were
increased. Importantly, anti-apoE antibody treatment improved
spatial learning performance during place trials in the MWM and
enhanced the resting-state bilateral functional connectivity in

different cortical regions. In vivo two-photon microscopic imaging demonstrated that HJ6.3 bound to A␤ plaques and cleared
some of them or led to their shrinkage, particularly those containing apoE. Together, the data suggest that further development of anti-apoE antibodies may be warranted as a potential
therapeutic strategy.
One of the major mechanisms for removal of the plaques in
response to some anti-A␤ antibodies is microglial-mediated
phagocytosis (Bard et al., 2000; Demattos et al., 2012). For apoE
passive immunotherapy, we previously observed an increase of
reactive microglia with a 14 d short-term passive immunization
with HJ6.3 (Kim et al., 2012), suggesting the involvement of microglia in the antibody-mediated A␤ removal. In the present
study, 5 months of weekly administration of the anti-apoE antibody HJ6.3 decreased microglial activity. This time-dependent
change in microglial activation agrees with the pattern observed
with A␤ passive immunization, in which short-term A␤ antibody
administration with certain anti-A␤ antibodies increases reactive
microglia whereas long-term administration decreases reactive
microglia (Wilcock et al., 2003; Wilcock et al., 2004b). The decrease of microglial activation associated with long-term immu-
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Figure 12. Reduction of the number of amyloid plaques after acute exposure with the antiapoE antibody HJ6.3. Fifty microliters of the anti-apoE antibody HJ6.3 or anti-HA control antibody (1.0 mg/ml) were topically applied to the brain surface of 5- to 7-month-old APP/PS1
mice. A, Fifteen days after application, amyloid plaques were stained with the rabbit antihuman A␤ (N) antibody (Immuno-Biological Laboratories). Scale bars: top, 2 mm; bottom, 100
m. B, C, Bar graphs summarizing the amyloid load (B) and plaque number (C) quantified in
the cortical region under the cranial window, normalized to the amount of plaques within the
hippocampus. D, Graph bar representing the plaque size distribution between the application of
the control antibody and the anti-apoE antibody HJ6.3 (n ⫽ 9/group; *p ⬍ 0.05, nonparametric Mann–Whitney test).

nization is likely a consequence of reduced plaque load and
associated microgliosis (Liu et al., 2001). Although our present
study does not rule out the possibility that anti-apoE antibodymediated phagocytosis plays a role in the clearance of A␤ colocalized with apoE in the plaques, it may suggest that apoE
antibody could suppress A␤ pathology through additional mechanisms via modifying apoE levels or function. ApoE plays an
important role in amyloidosis progression (Dodart et al., 2005;
Hudry et al., 2013). Previous work has shown that apoE colocalizes with newly formed A␤ deposits and that apoE4 carriers show
more apoE containing newly formed plaques than individuals
with other apoE genotypes, suggesting the involvement of apoE
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in the initiation of plaque formation (Thal et al., 2005). In the
chronic treatment experiment of the present study, HJ6.3 was
more effective at decreasing A␤ deposits in thalamus than in
cortex and hippocampus, likely due to the fact that thalamus has
fewer initial preexisting plaques than cortex and hippocampus.
Furthermore, the fact that chronic but not acute application of
anti-apoE antibody decreased fibrillar plaques may also suggest
that the major effect of the anti-apoE antibody was to suppress
amyloidosis progression, as opposed to removing preexisting
plaques.
The in vivo two-photon microscopy experiments provided
direct evidence that the anti-apoE antibody prevented the formation of new plaques and decreased the size of existing plaques
upon binding. This was particularly true for plaques containing
apoE. Collectively, our data suggest that the anti-apoE antibody
HJ6.3 is able to suppress further A␤ deposition and to enhance
the clearance or shrinkage of a small percentage of plaques after
antibody application if plaques are bound by the HJ6.3 antibody.
Importantly, when peripherally administrated into mice with
preexisting A␤ deposition, the anti-apoE antibody HJ6.3 was able
to improve spatial learning performance and functional connectivity in addition to its effects on A␤ pathology.
The role of apoE in AD pathogenesis has been studied extensively, but there is still debate regarding whether increasing or
decreasing apoE is the best strategy in regard to AD therapeutics
(Ashford, 2002; Teter et al., 2002). LXR agonists have been shown
to decrease A␤ deposition in the brain while modestly increasing
apoE expression (Koldamova et al., 2005; Zelcer et al., 2007; Fitz
et al., 2010). However, these agents also strongly increase apoE
lipidation by increasing ABCA1 and affecting other inflammatory mechanisms. Conversely, blocking the interaction between
apoE and A␤ (Sadowski et al., 2006) and decreasing the apoE
level by overexpressing low-density lipoprotein receptor (Kim et
al., 2009) or haploinsufficiency of apoE (Bales et al., 1999; Holtzman et al., 2000; Kim et al., 2011; Bien-Ly et al., 2012) results in
decreased amyloidosis. The anti-apoE antibody in the present
study did not alter plasma apoE levels while decreasing apoE level
in the brain, as detected by immunostaining associated with
plaques, providing evidence that lowering A␤-associated apoE in
the brain plays a beneficial role in A␤-amyloid-related pathogenesis. Interestingly, using biochemical analysis after anti-apoE antibody treatment, apoE levels decreased mainly in the Triton
X-100 fraction of the cortical tissue extract. It is unlikely that the
change of apoE in the Triton X-100 fraction is only a consequence
of the reduction of coaggregated A␤ in the Triton X-100 fraction
because, if this were the case, we would have expected apoE to
decrease in the guanidine fraction where the A␤ levels changed as
well. In fact, the apoE level in the guanidine fraction was not
changed. Triton X-100 is a nonionic detergent that is widely used
to extract molecules and lipids from lipid-containing structures
such as cell membranes. Our observation suggests the possibility
that the anti-apoE antibody HJ6.3 targeted apoE associated with
brain lipids and suppressed amyloidosis.
Interestingly, the anti-apoE antibody HJ6.3 increased plasma
A␤ levels without affecting plasma apoE. For certain A␤ antibodies, such as m266, increases of peripheral A␤ has been observed
because antibody prevented A␤ from being degraded via binding
to it and potentially increasing net A␤ efflux out of the brain
(DeMattos et al., 2002; Yamada et al., 2009). If a similar mechanism occurred in the present study, then apoE antibody could
stabilize apoE as well as A␤ associated with apoE. However, we
found that the plasma apoE level did not increase along with A␤
levels upon binding with antibodies. Therefore, the increase of
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plasma A␤ could be mediated through another mechanism that is
due to a central or peripheral effect. Expression of apoE3 and
apoE4 in the mouse brain results in diminished efflux of A␤ into
the blood compared with apoE2 (Hudry et al., 2013). Overexpression of an apoE receptor, a low-density lipoprotein receptor,
lowers the brain apoE level and enhances the rate of brain-toblood transportation of A␤ (Castellano et al., 2012). In the present study, HJ6.3 may be enhancing A␤ transport across the BBB
or enhancing its CSF/ISF to plasma flow via decreasing the apoE
level or sequestering apoE.
Increased CAA and CAA-associated microhemorrhage (Pfeifer et al., 2002; Wilcock et al., 2004a) are side effects associated
with previous passive A␤ immunotherapy, especially with those A␤
antibodies that target aggregated forms of A␤ if the effector function of the antibody is intact (Pfeifer et al., 2002; Wilcock et al.,
2004a; Racke et al., 2005). The mechanism of the anti-A␤
antibody-induced increase of CAA associated microhemorrhage
is not entirely clear. The anti-apoE antibody HJ6.3 did not cause
a detectable increase of CAA or CAA-associated microhemorrhages. This may be due to the anti-apoE antibody enhancing
both apoE and A␤ clearance, but via a different mechanism from
certain A␤ antibodies that favor A␤ clearance but may enhance
A␤ transport along the interstitial fluid surrounding arterioles
where CAA forms. Although apoE is known to play a key role in
CAA development (Holtzman et al., 2000; Fryer et al., 2003),
therapeutic antibodies targeting apoE may induce fewer or no
side effects associated with CAA. The somewhat modest effect of
the anti-apoE antibody HJ6.3 on established CNS amyloid levels
may also contribute to the lack of CAA and CAA-associated brain
microhemorrhages. In addition, the APP/PS1 mice that we used
in these studies had a relatively small amount of CAA. In future
studies, it will be important to compare some of the differences in
anti-A␤-associated versus anti-apoE-associated effects of CAA
and CAA-associated brain hemorrhage in another mouse model.
In addition, it will be important to assess the effects of anti-apoE
antibodies in animals that express human apoE isoforms. Such
experiments may lead to a better understanding of the involvement and consequences of both apoE and A␤ in plaque and CAA
formation and aid in treatment development.
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